Clinical Trial Update: A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating INCAGN01949 in combination with immune therapies for advanced or metastatic malignancies has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignancies

Drugs mentioned

• INCAGN01949

Snippet

Sponsor: Incyte Biosciences International Sàrl | Conditions: Advanced Malignancies | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-09-27